Telix Pharmaceuticals received FDA agreement to advance Part 2 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration resistant prostate cancer in the U.S. The FDA approved the clinical protocol, statistical plan, and safety data from Part 1, allowing the study to expand with randomized cohorts combining TLX591-Tx and standard therapies. This progress supports ongoing international enrollment and pending regulatory submissions in Europe. The trial aims to offer a new radiopharmaceutical treatment option with fewer side effects and flexible integration into existing therapies.
Idaho Copper Corporation announced an $18 million public offering of common stock and warrants priced at $4.85 per share, with an additional 45-day option for over-allotments. The proceeds will fund an updated Preliminary Economic Assessment, initial...
The global neonatal infant care market, valued at $3.06 billion in 2025, is projected to grow to $5.59 billion by 2035 at a CAGR of 6.21%. Growth is driven by increasing preterm births and neonatal complications like respiratory disorders and jaundic...
The FDA has approved Casgevy, a gene therapy using CRISPR technology, for children aged 2 and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT). This therapy modifies patients' own stem cells to increase fetal hemo...
ClearBridge Energy Midstream Opportunity Fund (EMO) maintains a hold rating due to its attractive 8.6% monthly dividend yield, supported by earnings and tax-efficient distributions. However, the fund's concentrated exposure to a few midstream energy ...
Velvet (VELVET) surged past the $2 mark to reach $2.17 following news of a partnership with Aerodrome Finance, but has since pulled back with an 11.5% correction and decreased trading volume. Despite the recent sell-off, buying volume remains strong,...
